These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 16899462)

  • 1. Multiple antigenic mimotopes of HIV carbohydrate antigens: relating structure and antigenicity.
    Pashov AD; Plaxco J; Kaveri SV; Monzavi-Karbassi B; Harn D; Kieber-Emmons T
    J Biol Chem; 2006 Oct; 281(40):29675-83. PubMed ID: 16899462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigenic properties of peptide mimotopes of HIV-1-associated carbohydrate antigens.
    Pashov A; Canziani G; Monzavi-Karbassi B; Kaveri SV; Macleod S; Saha R; Perry M; Vancott TC; Kieber-Emmons T
    J Biol Chem; 2005 Aug; 280(32):28959-65. PubMed ID: 15955803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting carbohydrate antigens in HIV vaccine development.
    Pashov A; Canziani G; Macleod S; Plaxco J; Monzavi-Karbassi B; Kieber-Emmons T
    Vaccine; 2005 Mar; 23(17-18):2168-75. PubMed ID: 15755589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigenic and immunological mimicry of peptide mimotopes of Lewis carbohydrate antigens.
    Luo P; Agadjanyan M; Qiu J; Westerink MA; Steplewski Z; Kieber-Emmons T
    Mol Immunol; 1998 Sep; 35(13):865-79. PubMed ID: 9839555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Priming characteristics of peptide mimotopes of carbohydrate antigens.
    Monzavi-Karbassi B; Shamloo S; Kieber-Emmons M; Jousheghany F; Luo P; Lin KY; Cunto-Amesty G; Weiner DB; Kieber-Emmons T
    Vaccine; 2003 Jan; 21(7-8):753-60. PubMed ID: 12531355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant.
    Wen Y; Trinh HV; Linton CE; Tani C; Norais N; Martinez-Guzman D; Ramesh P; Sun Y; Situ F; Karaca-Griffin S; Hamlin C; Onkar S; Tian S; Hilt S; Malyala P; Lodaya R; Li N; Otten G; Palladino G; Friedrich K; Aggarwal Y; LaBranche C; Duffy R; Shen X; Tomaras GD; Montefiori DC; Fulp W; Gottardo R; Burke B; Ulmer JB; Zolla-Pazner S; Liao HX; Haynes BF; Michael NL; Kim JH; Rao M; O'Connell RJ; Carfi A; Barnett SW
    PLoS One; 2018; 13(4):e0194266. PubMed ID: 29698406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining carbohydrate antigens as HIV vaccine candidates.
    Pashov A; Perry M; Dyar M; Chow M; Kieber-Emmons T
    Curr Pharm Des; 2007; 13(2):185-201. PubMed ID: 17269927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations.
    Newman MJ; Wu JY; Gardner BH; Anderson CA; Kensil CR; Recchia J; Coughlin RT; Powell MF
    Vaccine; 1997 Jun; 15(9):1001-7. PubMed ID: 9261947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human immunodeficiency virus type 1 Nef epitopes recognized in HLA-A2 transgenic mice in response to DNA and peptide immunization.
    Sandberg JK; Leandersson AC; Devito C; Kohleisen B; Erfle V; Achour A; Levi M; Schwartz S; Kärre K; Wahren B; Hinkula J
    Virology; 2000 Jul; 273(1):112-9. PubMed ID: 10891413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mimicry of native peptide antigens by the corresponding retro-inverso analogs is dependent on their intrinsic structure and interaction propensities.
    Nair DT; Kaur KJ; Singh K; Mukherjee P; Rajagopal D; George A; Bal V; Rath S; Rao KV; Salunke DM
    J Immunol; 2003 Feb; 170(3):1362-73. PubMed ID: 12538696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploiting molecular mimicry: defining rules of the game.
    Cunto-Amesty G; Luo P; Monzavi-Karbassi B; Kieber-Emmons T
    Int Rev Immunol; 2001; 20(2):157-80. PubMed ID: 11878763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Galalpha1-3Galbeta1-4GlcNAc-R epitopes.
    Abdel-Motal U; Wang S; Lu S; Wigglesworth K; Galili U
    J Virol; 2006 Jul; 80(14):6943-51. PubMed ID: 16809300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Directing the immune response to carbohydrate antigens.
    Cunto-Amesty G; Dam TK; Luo P; Monzavi-Karbassi B; Brewer CF; Van Cott TC; Kieber-Emmons T
    J Biol Chem; 2001 Aug; 276(32):30490-8. PubMed ID: 11384987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conformational changes of gp120 in epitopes near the CCR5 binding site are induced by CD4 and a CD4 miniprotein mimetic.
    Zhang W; Canziani G; Plugariu C; Wyatt R; Sodroski J; Sweet R; Kwong P; Hendrickson W; Chaiken I
    Biochemistry; 1999 Jul; 38(29):9405-16. PubMed ID: 10413516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular recognition of a peptide mimic of the Lewis Y antigen by an anti-Lewis Y antibody.
    Murali R; Kieber-Emmons T
    J Mol Recognit; 1997; 10(6):269-76. PubMed ID: 9770651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokeratin peptide SFGSGFGGGY mimics N-acetyl-beta-D-glucosamine in reaction with antibodies and lectins, and induces in vivo anti-carbohydrate antibody response.
    Shikhman AR; Greenspan NS; Cunningham MW
    J Immunol; 1994 Dec; 153(12):5593-606. PubMed ID: 7527445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A survey of synthetic HIV-1 peptides with natural and chimeric sequences for differential reactivity with Zimbabwean, Tanzanian and Swedish HIV-1-positive sera.
    Blomberg J; Lawoko A; Pipkorn R; Moyo S; Malmvall BE; Shao J; Dash R; Tswana S
    AIDS; 1993 Jun; 7(6):759-67. PubMed ID: 8363754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide mimotopes of carbohydrate antigens.
    Kieber-Emmons T
    Immunol Res; 1998; 17(1-2):95-108. PubMed ID: 9479572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee.
    Nicely NI; Wiehe K; Kepler TB; Jaeger FH; Dennison SM; Rerks-Ngarm S; Nitayaphan S; Pitisuttithum P; Kaewkungwal J; Robb ML; O'Connell RJ; Michael NL; Kim JH; Liao HX; Munir Alam S; Hwang KK; Bonsignori M; Haynes BF
    EBioMedicine; 2015 Jul; 2(7):713-22. PubMed ID: 26288844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxic T lymphocytes recognize structurally diverse, clade-specific and cross-reactive peptides in human immunodeficiency virus type-1 gag through HLA-B53.
    Dorrell L; Willcox BE; Jones EY; Gillespie G; Njai H; Sabally S; Jaye A; DeGleria K; Rostron T; Lepin E; McMichael A; Whittle H; Rowland-Jones S
    Eur J Immunol; 2001 Jun; 31(6):1747-56. PubMed ID: 11385619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.